Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

Fig. 1

a Immunoblot analysis of CCDC6 and USP7 in the J82, T24, 5637, KU-19-19 bladder cancer cells. Anti-tubulin is shown as loading control. b P5091 exerts a cytotoxic effect on bladder cancer cells, J82 [7.9 μM IC50], T24 [4.21 μM IC50], 5637 [4.90 μM IC50] and KU-19-19 [4.83 μM IC50] . Cells were seeded in 96-well plates and 24 h later exposed to the vehicle (DMSO) or to P5091 at the indicated doses for 144 h. The viability of cells at 50% inhibitory concentration [IC50] value was analysed using a modified 3-(4,5-dimethylthiazole-2-yl)-2–5-diphenyltetrazolium bromide assay, CellTiter 96 Aqueous one Solution assay (Promega), The values are presented as mean standard deviation of three independent experiments. c, d, e, f J82, T24, 5637 and KU-19-19 cells were pretreated with P5091 [12.5 μM] for 4 h, or with DMSO, and exposed to cycloheximide (CHX) [50 μg/ml] for the indicated times. Total protein lysates were subjected to immunoblot analysis using anti-CCDC6 and anti-PCNA antibodies

Back to article page